# Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale
Canonical URL: https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-announces-publication-establishing-clinically-meaningful-improvement-threshold-for-the-tardive-dyskinesia-impact-scale
Ticker: NBIX
Company: Neurocrine Biosciences
Source: Neurocrine Biosciences
Published: 2026-04-29 20:05 EST
Original Source URL: https://neurocrine.gcs-web.com
## Summary

Research published in The   Journal of Clinical Psychiatry characterizes patient-reported improvement with INGREZZA ® (valbenazine) capsules across the KINECT ® clinical program Publication establishes a clinically meaningful improvement threshold for the Tardive Dyskinesia Impact Scale (TDIS™) SAN

## Article Body
Research published in The   Journal of Clinical Psychiatry characterizes patient-reported improvement with INGREZZA ® (valbenazine) capsules across the KINECT ® clinical program Publication establishes a clinically meaningful improvement threshold for the Tardive Dyskinesia Impact Scale (TDIS™) SAN
## Recent Company News
- 2026-06-03 12:30 EST — [Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-to-present-new-two-year-crenessityr-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026) — Source: Neurocrine Biosciences
- 2026-05-26 20:01 EST — [Neurocrine Biosciences to Present at Upcoming Investor Conferences in June](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-to-present-at-upcoming-investor-conferences-in-june) — Source: Neurocrine Biosciences
- 2026-05-18 20:05 EST — [Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-presents-real-world-data-highlighting-functional-impact-of-mild-tardive-dyskinesia-severity-and-improvement-with-ingrezzar-valbenazine-capsules) — Source: Neurocrine Biosciences
- 2026-05-18 12:46 EST — [Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-completes-acquisition-of-soleno-therapeutics) — Source: Neurocrine Biosciences
- 2026-05-06 12:30 EST — [Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-announces-publication-of-expert-recommendations-for-glucocorticoid-dose-reduction-after-initiating-crenessityr-crinecerfont-for-the-treatment-of-classic-congenital-adrenal-hyperplasia) — Source: Neurocrine Biosciences
## Related News
- 2026-07-22 20:15 EST — BFRG — [BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-the-btig-virtual-biotechnology-conference-5880a10e)
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)